Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Atheroscler Suppl

Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DisFeB), University of Milan, Milan, Italy; IRCCS MultiMedica Hospital, Sesto S. Giovanni, Milan, Italy.

Published: December 2020

Background And Aim: The metabolic syndrome (MetS) has become one of the most important clinical issues in the cardiovascular field for this decade because of the marked increase in cardiovascular (CV) risk associated with a clustering of risk factors. The aim of the current study was to evaluate the relationship between MetS and its components and cardiovascular disease (CVD).

Methods: This population-based cross-sectional study was based on data from two studies carried out in Russia (ESSE-RF) and Italy (PLIC). One sample from each cohort was selected, matching individuals by sex and age. A comparison between samples of MetS components distribution and CV risk, according to SCORE chart, has been conducted.

Results: A total of 609 individuals (mean [SD] age 55 [8] years, about 39% males) for each cohort were selected. Almost half of PLIC cohort participants belonged to the moderate CV risk group (47% vs 27%), while in ESSE-RF cohort a relatively higher prevalence of individuals classified in the high and very high risk group was observed (19% vs 11%, 21% vs 6%, respectively). Overall, 43% of ESSE-RF participants were diagnosed with MetS, compared with the 27% of PLIC members (the difference in prevalence becomes 37% vs 21%, considering a more conservative cut-off for waist circumference). Both cohorts showed a trend towards the increase of MetS components moving from the lowest to the highest CV risk class, with a high prevalence of patients with four or five MetS determinants allocated in the high/very high CV risk group.

Conclusions: Developing effective public health strategies for the prevention, detection and treatment of MetS should be an urgent priority to reduce the burden of CVD, not only in subjects at high/very high CV risk, but also in those characterized by a lower risk, as even rare CV events that come from low risk group bring a tangible burden to healthcare systems.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2021.01.008DOI Listing

Publication Analysis

Top Keywords

mets components
12
risk group
12
high risk
12
risk
11
metabolic syndrome
8
cardiovascular disease
8
cohort selected
8
high/very high
8
mets
7
high
5

Similar Publications

Introduction: Metabolic syndrome (MetS) and chronic kidney disease are both important risk factors for cardiovascular disease and are closely related to each other. We retrospectively investigated whether MetS or its components increase the risk of development of impaired kidney function in the Japanese general population.

Methods: This is a retrospective cohort study which enrolled 14917 participants who visited our hospital for physical checkups from 2008 to 2018 and had normal estimated glomerular filtration rate (eGFR≥60 mL/min/1.

View Article and Find Full Text PDF

Background: The number of people reaching old age is rising, bringing an increase in age-related diseases like cardiovascular conditions and cognitive dysfunction. Cognitive impairment (CI) impacts various brain functions, affecting daily activities and quality of life. Metabolic syndrome (MetS), a cluster of cardiovascular risk factors, has been implicated in CI.

View Article and Find Full Text PDF

Associations between plasma caspase-1 levels and cardiovascular disease, with the mediating role of metabolic syndrome.

Atherosclerosis

December 2024

Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan, China. Electronic address:

Aims: This study aimed to explore the association between plasma caspase-1 levels and cardiovascular disease (CVD), as well as the potential mediating role of metabolic syndrome (Mets) in the association.

Methods: This study analyzed the UK Biobank Precision Proteomics Project (UKB-PPP), which detected plasma caspase-1 levels in participants. CVD was defined by ICD-9/ICD-10 codes.

View Article and Find Full Text PDF

Background: Given the rapid increase in the prevalence of prostate cancer (PCa), identifying its risk factors and developing suitable risk prediction models has important implications for public health. We used machine learning (ML) approach to screen participants with high risk of PCa and, specifically, investigated whether participants with metabolic syndrome (MetS) exhibited an elevated PCa risk.

Methods: A prospective cohort study was performed with 41,837 participants in South Korea.

View Article and Find Full Text PDF

Background: The global prevalence of metabolic syndrome (MetS) in people living with HIV (PLWH) is on the rise in the post era of antiretroviral therapy (ART). Nevertheless, there are no validated predictive models available for assessing the risk of MetS in this specific population.

Methods: This study included PLWH who participated in annual follow-ups at Southern Medical University Nanfang Hospital from September 2022 to November 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!